In this study, the concentrations of anti-IL26 mAb used were much lower than the concentrations reported necessary for the antimicrobial effects of IL26. This allows for further evaluation of anti-IL26 mAb as a therapeutic target in inflammatory diseases like psoriasis, PsA and axSpA. This evidence concerns the gene IL26 and psoriasis.